XOMA - XOMA Corp Stock Price, Fair Value and News

25.69USD+0.03 (+0.12%)Delayed

Market Summary

USD25.69+0.03

Delayed

0.12%

XOMA Stock Price

View Fullscreen

XOMA RSI Chart

XOMA Valuation

Market Cap

299.0M

Price/Earnings (Trailing)

-7.55

Price/Sales (Trailing)

51.45

EV/EBITDA

-6.74

Price/Free Cashflow

-16.43

XOMA Price/Sales (Trailing)

XOMA Profitability

Operating Margin

97.79%

EBT Margin

-702.12%

Return on Equity

-48.11%

Return on Assets

-18.05%

Free Cashflow Yield

-6.09%

XOMA Fundamentals

XOMA Revenue

Revenue (TTM)

5.8M

Rev. Growth (Yr)

240.96%

Rev. Growth (Qtr)

-18.71%

XOMA Earnings

Earnings (TTM)

-39.6M

Earnings Growth (Yr)

12.41%

Earnings Growth (Qtr)

57.26%

Breaking Down XOMA Revenue

Last 7 days

1.0%

Last 30 days

5.9%

Last 90 days

11.1%

Trailing 12 Months

25.4%

How does XOMA drawdown profile look like?

XOMA Financial Health

Current Ratio

9.45

Debt/Equity

1.39

Debt/Cashflow

-0.16

XOMA Investor Care

Shares Dilution (1Y)

1.55%

Diluted EPS (TTM)

-3.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.8M	0	0	0
2023	3.4M	4.0M	4.4M	4.8M
2022	40.9M	41.0M	40.5M	6.0M
2021	31.6M	33.8M	36.0M	38.2M
2020	11.0M	10.5M	2.2M	29.4M
2019	13.0M	11.7M	19.6M	18.4M
2018	40.8M	29.0M	17.1M	5.3M
2017	17.3M	29.1M	40.9M	52.7M
2016	56.8M	54.7M	53.2M	5.6M
2015	18.1M	14.7M	11.6M	55.4M
2014	29.4M	28.2M	27.1M	18.9M
2013	33.4M	31.2M	30.3M	35.5M
2012	52.5M	45.2M	36.2M	33.8M
2011	43.3M	52.6M	57.9M	58.2M
2010	82.2M	66.0M	49.8M	33.6M
2009	0	0	0	98.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of XOMA Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 03, 2023	sitko bradley	bought	3,472	13.89	250	chief investment officer
Oct 02, 2023	sitko bradley	bought	21,375	14.25	1,500	chief investment officer
Oct 02, 2023	hughes owen	bought	13,830	13.83	1,000	exec chairman and interim ceo
Sep 26, 2023	hughes owen	bought	36,060	14.43	2,499	exec chairman and interim ceo
Sep 25, 2023	hughes owen	bought	14.65	14.65	1.00	exec chairman and interim ceo
May 31, 2023	sitko bradley	bought	25,700	17.1333	1,500	chief investment officer
May 24, 2023	hughes owen	bought	24,551	23.79	1,032	interim ceo
May 23, 2023	sitko bradley	bought	16,150	19.00	850	chief investment officer
May 23, 2023	hughes owen	bought	22,706	23.4569	968	interim ceo
May 19, 2023	sitko bradley	bought	19,500	19.5	1,000	chief investment officer

Which funds bought or sold XOMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.9	-4,579	17,677	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-227,069	-	-%
May 15, 2024	DEUTSCHE BANK AG\	reduced	-3.58	22,548	111,496	-%
May 15, 2024	MORGAN STANLEY	added	923	3,540,730	3,828,350	-%
May 15, 2024	STATE STREET CORP	added	11.67	1,039,900	3,341,720	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	new	-	212,000	212,000	-%
May 15, 2024	FIRST MANHATTAN CO. LLC.	unchanged	-	27,750	120,250	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-63.03	-101,937	94,348	-%
May 15, 2024	BARCLAYS PLC	reduced	-48.84	-63,000	124,000	-%
May 15, 2024	Opaleye Management Inc.	unchanged	-	1,387,500	6,012,500	1.38%

Are Funds Buying or Selling XOMA?

Are funds buying XOMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XOMA

No. of Funds

Unveiling XOMA Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 16, 2024	biotechnology value fund l p	15.6%	1,789,844	SC 13D/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2022	eagle point credit management llc	0.0%	0	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G
Apr 19, 2021	eagle point credit management llc	6.3%	149,248	SC 13G
Apr 02, 2021	biotechnology value fund l p	15.6%	1,760,384	SC 13D/A
Dec 15, 2020	biotechnology value fund l p	18.5%	2,040,124	SC 13D/A
Oct 09, 2020	biotechnology value fund l p	18.5%	2,040,124	SC 13D/A
Sep 23, 2020	biotechnology value fund l p	18.5%	2,040,124	SC 13D/A

Recent SEC filings of XOMA Corp

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 16, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report

Peers (Alternatives to XOMA Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

XOMA Corp News

Latest updates

XOMA Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-18.7%	1,490,000	1,833,000	830,000	1,658,000	437,000	1,486,000	451,000	983,000	3,107,000	35,945,000	940,000	901,000	14,240,500	27,580,000	556,000	444,000	804,000	422,000	8,855,000	962,000	8,131,000
Operating Expenses	-61.0%	8,494,000	21,767,000	6,617,000	7,615,000	10,607,000	7,696,000	4,823,000	5,750,000	5,172,000	5,579,500	4,285,000	3,965,000	6,802,000	3,708,000	3,246,000	3,595,000	6,420,000	4,423,000	5,964,000	5,673,000	6,195,000
S&GA Expenses	-100.0%	-	7,265,000	6,368,000	5,777,000	6,196,000	7,571,000	4,794,000	5,710,000	5,116,000	5,537,500	4,255,000	3,927,000	6,741,000	3,672,500	3,212,000	3,557,000	6,358,000	4,293,000	5,821,000	4,949,000	5,939,000
R&D Expenses	32.0%	33,000	25,000	25,000	39,000	54,000	28,000	29,000	40,000	56,000	42,000	30,000	38,000	61,000	36,000	34,000	38,000	62,000	130,000	143,000	724,000	256,000
EBITDA Margin	18.1%	-6.92	-8.46	-3.77	-4.13	-4.96	-2.76	0.40	0.40	0.40	0.43	0.26	0.39	-	-	-	-	-	-	-	-	-
Interest Expenses	-	3,551,000	-	-	-	-	-	-	-	-	-	-	172,000	289,000	360,000	434,000	508,000	542,000	583,000	484,000	423,000	429,000
Income Taxes	-	-	-	-	-	-	-110,000	-	-	95,000	91,000	-	-	-	25,000	26,000	-26,000	-1,500,000	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	29,935,000	-4,436,000	-2,237,000	-7,373,000	22,691,000	-1,077,000	-3,533,000	-6,284,000	-4,321,000	3,178,000	-4,072,000	3,233,000
EBT Margin	18.1%	-7.02	-8.58	-3.88	-4.25	-5.10	-2.84	0.39	0.39	0.39	0.42	0.24	0.36	-	-	-	-	-	-	-	-	-
Net Income	57.3%	-8,595,000	-20,109,000	-5,509,000	-5,400,000	-9,813,000	-5,976,000	-4,178,000	-4,670,000	-2,280,000	29,844,000	-4,436,000	-2,237,000	-7,373,000	22,666,000	-1,077,000	-3,533,000	-4,758,000	-4,321,000	3,178,000	-4,072,000	3,233,000
Net Income Margin	20.6%	-6.82	-8.58	-6.05	-6.29	-7.34	-2.84	0.46	0.45	0.51	0.41	0.24	0.35	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-4,964,000	-	-2,099,000	-7,208,000	-4,924,000	-3,890,000	-3,663,000	-4,317,000	-1,009,000	30,642,000	-3,075,000	-3,975,000	-914,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.4%	219	234	124	126	134	140	146	154	159	167	131	136	120	125	86.00	88.00	92.00	96.00	86.00	78.00	76.00
Current Assets	-13.2%	147	169	35.00	38.00	45.00	61.00	80.00	87.00	90.00	97.00	75.00	87.00	70.00	88.00	48.00	52.00	56.00	60.00	44.00	46.00	51.00
Cash Equivalents	-7.1%	142	153	33.00	31.00	44.00	58.00	78.00	83.00	89.00	95.00	72.00	84.00	70.00	86.00	46.00	49.00	53.00	57.00	40.00	42.00	48.00
Net PPE	60.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-5.8%	137	146	18.00	16.00	19.00	16.00	16.00	19.00	19.00	25.00	19.00	19.00	38.00	39.00	48.00	49.00	51.00	52.00	60.00	57.00	52.00
Current Liabilities	-20.3%	16.00	19.00	10.00	7.00	10.00	7.00	5.00	8.00	8.00	13.00	7.00	6.00	13.00	12.00	12.00	11.00	10.00	9.00	10.00	12.00	7.00
Long Term Debt	-3.4%	115	119	-	-	-	-	-	-	-	-	-	-	12.00	13.00	21.00	23.00	25.00	27.00	29.00	23.00	21.00
LT Debt, Current	10.8%	6.00	6.00	-	-	-	-	-	-	-	-	-	-	7.00	8.00	9.00	8.00	6.00	5.00	4.00	3.00	2.00
LT Debt, Non Current	-100.0%	-	119	-	-	-	-	-	-	-	-	-	-	12.00	13.00	21.00	23.00	25.00	27.00	29.00	23.00	21.00
Shareholder's Equity	-7.2%	82.00	89.00	106	110	115	124	130	135	140	142	112	117	82.00	86.00	38.00	38.00	41.00	44.00	26.00	21.00	24.00
Retained Earnings	-0.7%	-1,231	-1,223	-1,203	-1,197	-1,192	-1,182	-1,176	-1,172	-1,167	-1,165	-1,195	-1,190	-1,188	-1,181	-1,203	-1,202	-1,199	-1,194	-1,190	-1,193	-1,189
Additional Paid-In Capital	0.2%	1,314	1,312	1,309	1,308	1,307	1,306	1,307	1,307	1,307	1,307	1,307	1,307	1,270	1,267	1,242	1,241	1,240	1,238	1,216	1,214	1,213
Shares Outstanding	1.2%	12.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	124	-	-	-	155	-	-	-	240	-	-	-	137	-	-	-	94.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-26.0%	-4,947	-3,927	-2,099	-7,208	-4,924	-3,890	-3,663	-4,317	-1,009	30,642	-3,075	-3,975	-914	17,678	-2,436	-2,870	-2,280	-4,148	3,799	-3,093	3,157
Share Based Compensation	7.8%	2,856	2,649	2,717	2,163	1,570	988	805	837	978	1,750	779	768	2,898	692	708	773	1,788	1,690	500	56.00	1,728
Cashflow From Investing	-231.5%	-7,246	5,511	5,494	-4,482	-7,234	-15,247	26.00	-	-5,000	-6,000	-7,000	-	-13,500	-200	-	-	-	-	-13,000	-6,000	-300
Cashflow From Financing	-104.0%	-4,956	124,494	-1,368	-1,165	-1,368	-1,322	-1,260	-1,134	-735	-1,439	-1,536	17,810	-2,000	23,161	-1,321	-951	-1,096	21,092	6,618	2,984	-201
Dividend Payments	-100.0%	-	1,368	1,368	1,368	1,368	1,368	1,368	1,368	1,368	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XOMA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenue from contracts with customers	$ 1,000
Revenue recognized under units-of-revenue method	490	$ 437
Total revenues	1,490	437
Operating expenses:
Research and development	33	54
General and administrative	8,461	6,196
Arbitration settlement costs		4,132
Amortization of intangible assets		225
Total operating expenses	8,494	10,607
Loss from operations	(7,004)	(10,170)
Other income (expense):
Interest expense	(3,551)
Other income (expense), net	1,960	357
Net loss	(8,595)	(9,813)
Comprehensive loss	(8,595)	(9,813)
Less: accumulated dividends on Series A and Series B preferred stock	(1,368)	(1,368)
Net loss attributable to common stockholders, basic	(9,963)	(11,181)
Net loss attributable to common stockholders, diluted	$ (9,963)	$ (11,181)
Basic net loss per share attributable to common stockholders (in dollars per share)	$ (0.86)	$ (0.98)
Diluted net loss per share attributable to common stockholders (in dollars per share)	$ (0.86)	$ (0.98)
Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)	11,580	11,460
Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)	11,580	11,460

XOMA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 136,225	$ 153,290
Short-term restricted cash	160	160
Short-term equity securities	413	161
Trade and other receivables, net	3	1,004
Short-term royalty and commercial payment receivables	9,819	14,215
Prepaid expenses and other current assets	270	483
Total current assets	146,890	169,313
Long-term restricted cash	6,016	6,100
Property and equipment, net	40	25
Operating lease right-of-use assets	364	378
Long-term royalty and commercial payment receivables	65,577	57,952
Other assets - long term	533	533
Total assets	219,420	234,301
Current liabilities:
Accounts payable	1,515	653
Accrued and other liabilities	1,299	2,768
Contingent consideration under RPAs, AAAs and CPPAs	3,000	7,000
Operating lease liabilities	55	54
Unearned revenue recognized under units-of-revenue method	2,159	2,113
Preferred stock dividend accrual	1,368	1,368
Current portion of long-term debt	6,144	5,543
Total current liabilities	15,540	19,499
Unearned revenue recognized under units-of-revenue method - long-term	6,692	7,228
Long-term operating lease liabilities	319	335
Long-term debt	114,528	118,518
Total liabilities	137,079	145,580
Commitments and Contingencies (Note 10)
Stockholders' equity:
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,636,355 and 11,495,492 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	87	86
Additional paid-in capital	1,314,036	1,311,809
Accumulated deficit	(1,231,831)	(1,223,223)
Total stockholders' equity	82,341	88,721
Total liabilities and stockholders' equity	219,420	234,301
8.625% Series A Cumulative, Perpetual Preferred Stock
Stockholders' equity:
Preferred Stock	49	49
8.375% Series B Cumulative, Perpetual Preferred Stock
Stockholders' equity:
Preferred Stock
Convertible preferred stock
Stockholders' equity:
Preferred Stock

About XOMA Corp

XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets. The company was incorporated in 1981 and is headquartered in Emeryville, California.

CEO	Mr. Owen P. Hughes Jr.
WEBSITE	xoma.com
INDUSTRY	Biotechnology
EMPLOYEES	11

XOMA Corp Frequently Asked Questions

What is the ticker symbol for XOMA Corp? What does XOMA stand for in stocks?

XOMA is the stock ticker symbol of XOMA Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of XOMA Corp (XOMA)?

As of Fri May 17 2024, market cap of XOMA Corp is 298.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XOMA stock?

You can check XOMA's fair value in chart for subscribers.

What is the fair value of XOMA stock?

You can check XOMA's fair value in chart for subscribers. The fair value of XOMA Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of XOMA Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XOMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is XOMA Corp a good stock to buy?

The fair value guage provides a quick view whether XOMA is over valued or under valued. Whether XOMA Corp is cheap or expensive depends on the assumptions which impact XOMA Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XOMA.

What is XOMA Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, XOMA's PE ratio (Price to Earnings) is -7.55 and Price to Sales (PS) ratio is 51.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XOMA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on XOMA Corp's stock?

In the past 10 years, XOMA Corp has provided -0.099 (multiply by 100 for percentage) rate of return.